title: [Refractory anterior uveitis].
abstract: Treatment of anterior uveitis should be etiological when a cause has been identified and provided for any symptomatic case, using topical corticosteroids and mydriatics/cycloplegics. Periocular and systemic agents are then used in certified cases that prove to be refractory to first-line therapy. If anterior uveitis is still rebellious to treatment, the physician should evaluate the accuracy of the present therapy in case of an unsuspected cause of uveitis, or a particularly severe or chronic intraocular inflammation.
authors.affiliation: Service d'ophtalmologie, hôpital Claude-Huriez, rue Michel-Polonovski, 59037 Lille cedex, France. pierre.labalette@chru-lille.fr
authors.forename: P
authors.initials: P
authors.lastname: Labalette
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D002648:Child; D002908:Chronic Disease; D003937:Diagnosis, Differential; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D057129:Iridocorneal Endothelial Syndrome / Q000175:diagnosis; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009184:Mydriatics / Q000009:adverse effects / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014606:Uveitis, Anterior / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D009184:Mydriatics; D009883:Ophthalmic Solutions; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate